IL314769A - Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa - Google Patents

Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Info

Publication number
IL314769A
IL314769A IL314769A IL31476924A IL314769A IL 314769 A IL314769 A IL 314769A IL 314769 A IL314769 A IL 314769A IL 31476924 A IL31476924 A IL 31476924A IL 314769 A IL314769 A IL 314769A
Authority
IL
Israel
Prior art keywords
administration period
years
prior
subject
day
Prior art date
Application number
IL314769A
Other languages
English (en)
Hebrew (he)
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of IL314769A publication Critical patent/IL314769A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL314769A 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa IL314769A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
IL314769A true IL314769A (en) 2024-10-01

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314769A IL314769A (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Country Status (11)

Country Link
US (1) US20250144116A1 (https=)
EP (1) EP4479059A4 (https=)
JP (1) JP2025508359A (https=)
KR (1) KR20240148350A (https=)
CN (1) CN118695864A (https=)
AU (1) AU2023221393A1 (https=)
CA (1) CA3244131A1 (https=)
GB (1) GB2630719A (https=)
IL (1) IL314769A (https=)
MX (1) MX2024009995A (https=)
WO (1) WO2023159120A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) * 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
MX2021012548A (es) * 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
US20250144116A1 (en) 2025-05-08
CN118695864A (zh) 2024-09-24
WO2023159120A1 (en) 2023-08-24
KR20240148350A (ko) 2024-10-11
MX2024009995A (es) 2024-08-22
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
AU2023221393A1 (en) 2024-08-15
EP4479059A1 (en) 2024-12-25
JP2025508359A (ja) 2025-03-26
GB2630719A (en) 2024-12-04
GB202412566D0 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
IL314769A (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
Usha et al. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis
US9078864B2 (en) Agonists for antimicrobial peptide systems
Bannenberg et al. Lipoxins and novel 15‐epi‐lipoxin analogs display potent anti‐inflammatory actions after oral administration
HRP20160355T1 (hr) Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida
EA011074B1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
BRPI0912607A2 (pt) medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete
ITMI962356A1 (it) Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
Li et al. Genipin attenuates dextran sulfate sodium-induced colitis via suppressing inflammatory and oxidative responses
Lee et al. Piroxicam-β-cyclodextrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states
JP7588675B2 (ja) 脆弱ｘ症候群、アンジェルマン症候群又はレット症候群を含む発達障害の軽減又は治療のためのカルバメート化合物の使用
CN105263503A (zh) 含有类肝素、急效麻醉剂及缓冲液的稳定组合物
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
AU2010211491A1 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
MX2025009098A (es) Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos
EP1948161A4 (en) METHOD FOR PREVENTING AND TREATING PPAR-MEDIATED CONDITIONS WITH MACELIGNAN
Wang et al. Spinal microglial activation promotes perioperative social defeat stress-induced prolonged postoperative pain in a sex-dependent manner
JP2006527234A5 (https=)
JP2009539877A5 (https=)
RU2007138263A (ru) Противовоспалительные соединения
Wright et al. Stevens-Johnson syndrome associated with furosemide: a case report
RU2008101661A (ru) Замещенное циклическое соединение, способ его получения и его лекарственное применение
Moxon Toxicity of selenium‐cystine and some other organic selenium compounds
BRPI0609653A2 (pt) tratamento ou prevenção de prurido
Little Failure of magnesium in treatment of Irukandji syndrome